Cell & Gene

Sterile filtration of cell culture media requires a careful balance between microbial retention, throughput, and operating pressure. Testing with a high-fouling media surrogate compared five 0.2 µm multilayer PES filters under identical constant-flow conditions. The Thermo Scientific LifeASSURE PDA020 filter maintained lower upstream pressure and processed 1,051 L/m² before reaching the defined endpoint, delivering 34% greater capacity than the next-highest-performing membrane.

Chromatography intensification can improve productivity and resin utilization, but greater efficiency may introduce new risks to process robustness. Protein A capture presents distinct challenges, including balancing loading capacity, residence time, cycle count, column format, and operational consistency.

As monoclonal antibody production scales, conventional two-stage depth filtration can create significant facility and workflow challenges. Higher harvest volumes and cell densities often require more filters, increasing footprint demands and complicating operations. For volumes above 2,000 L, single-use centrifugation can replace primary depth filtration, reducing the number of clarifying filters needed while preparing the harvest stream for downstream purification.

BE BioSol is the biologics CDMO business of Biological E. Limited, combining more than 70 years of biopharmaceutical manufacturing experience with a growing, integrated development and manufacturing platform for global biopharma partners. With a strong track record supporting regulated markets and long-standing relationships with leading pharmaceutical companies, BE BioSol provides development, analytical, technology transfer, and commercial manufacturing solutions across biologics and vaccines.

Get more Cell & Gene insight with our FREE newsletter Newsletter | September 4, 2026 The evidence gap in Hematology: From trial endpoints to patient outcomes As hematology trials become more complex, sponsors face increasing pressure to accelerate development while generating stronger evidence, mitigating recruitment risk and supporting faster patient access.

LISTEN NOW: OUR LATEST PODCAST EPISODES Check out the latest episodes from Better Biopharma, Cell & Gene: The Podcast, and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

Successful viral vector scale‑up depends on early process design, predictive models, and execution strategies that anticipate GMP realities rather than simply increasing production volume. Adenoviruses are being reimagined as powerful tools for oncolytic cancer therapy, using their immunogenicity, tumor selectivity, and synergy with immunotherapy to drive new clinical progress.

By Sid Kerkar, MD, Founder and CEO, AllerGene AI Therapeutics My interest in applying CAR T cell therapy to allergic disease began at home. All three of my children were diagnosed with severe, life-threatening allergies, turning a disease I understood as a physician-scientist into something deeply personal.

Introducing our solution for commercial-scale DPI blister filling. Achieve accurate, clean, scalable powder dosing with our DPI Blister Filler, designed for commercial pharmaceutical manufacturing. Ideal for Dry powder inhaler (DPI) filling. Pharmaceutical teams working with magnesium stearate-based formulations. Commercial blister strip production. CDMOs requiring scalable blister filling technology.

Managing outsourced programs shouldn't mean dealing with fragmented spreadsheets and endless email chains to see where your project stands. By unifying your data into a single digital platform, you bring clear visibility to your programs for confident, informed decisions. Building a multi-product ATMP facility? Master the HVAC configuration, contamination controls, and N+1 redundancy an operations-first approach demands. Connect with facility experts and plan your next expansion with confidence.